Oric

The Orical Group of Companies Launches SuperVision Brokerage LLC

Retrieved on: 
Thursday, September 14, 2023
Asset Management, Professional Services, Finance, Oric, Supervision, Maxim, Marketing, Marriage, Broker-dealer, Trust, FINRA, Security (finance), Cryptocurrency

The Orical Group of Companies (the Orical Group), an award-winning investment management regulatory and compliance adviser, announced today the launch of SuperVision Brokerage LLC (SuperVision).

Key Points: 
  • The Orical Group of Companies (the Orical Group), an award-winning investment management regulatory and compliance adviser, announced today the launch of SuperVision Brokerage LLC (SuperVision).
  • SuperVision is a financial services company dedicated to providing strategic advisory and capital raising services to high-quality fund managers and private companies across various sectors.
  • SuperVision has also announced the appointment of Paul Mashkovich, formerly of Maxim Group LLC (Maxim), as Managing Director and Chief Growth Officer to cultivate the firm’s expansion.
  • It’s a perfect marriage of synergies that will bring a unique advantage to both investors and issuers within The Orical Group of Companies”, said Mr. Mashkovich.

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

Retrieved on: 
Tuesday, March 2, 2021
Lluís Companys, Origin of replication, Oric, Oppenheimer, Spanish politicians, Computing, Computers

ET / 4:00 a.m. PT; and

Key Points: 
  • ET / 4:00 a.m. PT; and
    Oppenheimer 31st Annual Healthcare Conference Presenting company overview on March 16, 2021 at 2:30 p.m.
  • Webcasts of each presentation will be available through the investor section of the companys website at www.oricpharma.com .
  • Beyond these four product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms.
  • ORIC has offices in South San Francisco and San Diego, California.

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

Retrieved on: 
Wednesday, February 3, 2021
Geography of California, Oric, Origin of replication, Lluís Companys, San Diego, Medication, California

A live webcast of the fireside chat will be available through the investor section of the companys website at www.oricpharma.com .

Key Points: 
  • A live webcast of the fireside chat will be available through the investor section of the companys website at www.oricpharma.com .
  • A replay of the webcast will be available for 90 days following the event.
  • Beyond these four product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms.
  • ORIC has offices in South San Francisco and San Diego, California.

ORIC Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 4, 2021
Life sciences, Health sciences, Pharmaceutical industry, Biotechnology, Medication, Biopharmaceutical, Pharmaceutical industry in China, Oric

A live webcast will be available through the investor section of the companys website at www.oricpharma.com .

Key Points: 
  • A live webcast will be available through the investor section of the companys website at www.oricpharma.com .
  • A replay of the webcast will be available for 90 days following the event.
  • ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients lives byOvercomingResistanceInCancer.
  • Beyond these four product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms.

ORIC Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Tuesday, November 17, 2020
Jefferies Group, Origin of replication, Underwriting, Oric, Computing, Computers

The gross proceeds to ORIC from the offering were approximately $133.3 million, before deducting underwriting discounts and commissions and estimated offering expenses.

Key Points: 
  • The gross proceeds to ORIC from the offering were approximately $133.3 million, before deducting underwriting discounts and commissions and estimated offering expenses.
  • J.P. Morgan Securities LLC, Citigroup,Jefferies LLC and Guggenheim Securities acted as joint book-running managers for the offering.
  • ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients lives by Overcoming Resistance In Cancer.
  • Beyond these four product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms.

ORIC Pharmaceuticals Announces Pricing of Upsized Public Offering

Retrieved on: 
Friday, November 13, 2020
Financial economics, Finance, Corporate finance, Money, Initial public offering, Stock market, Actuarial science, Underwriting, Oric, Stock, Public offering

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 13, 2020 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc.(Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the pricing of an upsized underwritten public offering of 5,040,000 shares of its common stock at a price of $23.00 per share.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 13, 2020 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc.(Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the pricing of an upsized underwritten public offering of 5,040,000 shares of its common stock at a price of $23.00 per share.
  • In addition, ORIC has granted the underwriters a 30-day option to purchase up to 756,000 additional shares of common stock at the public offering price, less the underwriting discounts and commissions.
  • The gross proceeds to ORIC from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by ORIC, are expected to be approximately $115.9 million, excluding any exercise of the underwriters option to purchase additional shares.
  • Such forward-looking statements include, among other things, statements regarding the terms, timing and completion of the public offering of common stock.

ORIC Pharmaceuticals Reports Third Quarter 2020 Financial and Operational Update

Retrieved on: 
Thursday, November 5, 2020
European Organisation for Research and Treatment of Cancer, Oric, Cash and cash equivalents, Computing, Computers

Expect to file IND/CTAs for ORIC-533, ORIC-944 and ORIC-114 in 2021

Key Points: 
  • Expect to file IND/CTAs for ORIC-533, ORIC-944 and ORIC-114 in 2021
    SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today reported financial results for the quarter ended September 30, 2020.
  • Preclinical Data on ORIC-101 Presented at EORTC-NCI-AACR: In October 2020, ORIC presented a poster and oral discussion at the 32nd EORTC-NCI-AACR Symposium 2020 that demonstrated ORIC-101 reversed glucocorticoid receptor (GR) mediated resistance to an androgen receptor (AR) degrader.
  • Cash, Cash Equivalents and Marketable Securities: Cash, cash equivalents and marketable securities totaled$186.6 millionas of September 30, 2020.
  • ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients lives by Overcoming Resistance In Cancer.

ORIC Pharmaceuticals Reports Second Quarter 2020 Financial and Operational Update

Retrieved on: 
Wednesday, August 5, 2020
American Association for Cancer Research, Oric, Origin of replication

ET

Key Points: 
  • ET
    SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 05, 2020 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today reported financial results for the quarter ended June 30, 2020.
  • Under the terms of the agreement with Mirati, ORIC paid to Mirati a one-time non-cash payment of $20 million in shares of ORIC common stock.
  • Preclinical Data on ORIC-101 Presented at AACR: In June 2020, ORIC presented three poster presentations at the 2020 American Association for Cancer Research (AACR) Annual Virtual Meeting II.
  • Preclinical Data on CD73 Inhibitor Program Presented at AACR: In June 2020, ORIC presented two poster presentations at the 2020 AACR Annual Virtual Meeting II.

ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive Worldwide License to Highly Selective Allosteric PRC2 Inhibitors from Mirati Therapeutics

Retrieved on: 
Wednesday, August 5, 2020
Organic compounds, Chemical compounds, Chemistry, Nonsteroidal antiandrogens, Progonadotropins, RTT, Nitriles, Enzalutamide, Prostate cancer, Oric, PRC2

With ORICs focus on novel treatments for prostate cancer, ORIC is an ideal partner to further the research and development of this program.

Key Points: 
  • With ORICs focus on novel treatments for prostate cancer, ORIC is an ideal partner to further the research and development of this program.
  • Prior to entering into the license agreement with Mirati, ORIC generated compelling in vivo efficacy data in enzalutamide-resistant prostate cancer models with ORIC-944.
  • More recent scientific advances have focused on developing allosteric inhibitors of PRC2, which may help to address several limitations of first-generation PRC2 inhibitors.
  • Research conducted at ORIC demonstrated that allosteric inhibitors of PRC2 are more efficacious in treatment-resistant prostate cancer models than has been reported by traditional non-allosteric PRC2 inhibitors.

ORIC Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Tuesday, April 28, 2020
Oric, Origin of replication, NASDAQ, Computing, Finance, Digital technology

The gross proceeds from the offering were $138.0 million, before deducting underwriting discounts and commissions and estimated offering expenses.

Key Points: 
  • The gross proceeds from the offering were $138.0 million, before deducting underwriting discounts and commissions and estimated offering expenses.
  • All of the shares were offered by ORIC.
  • The shares began trading on The Nasdaq Global Select Market on April 24, 2020, under the symbol ORIC.
  • ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients lives by Overcoming Resistance In Cancer.